
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>record_id</th><th>visit</th><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>PG001</td><td>1</td><td>Fluticasone furoate</td><td>Calcitriol</td><td>The therapeutic efficacy of Calcitriol can be decreased when used in combination
with Fluticasone furoate.</td></tr><tr><td>PG001</td><td>1</td><td>Fluticasone furoate</td><td>Lercanidipine</td><td>The metabolism of Fluticasone furoate can be decreased when combined with
Lercanidipine.</td></tr><tr><td>PG001</td><td>1</td><td>Fluticasone furoate</td><td>Levothyroxine</td><td>The therapeutic efficacy of Levothyroxine can be increased when used in
combination with Fluticasone furoate.</td></tr><tr><td>PG001</td><td>1</td><td>Fluticasone furoate</td><td>Levothyroxine</td><td>The therapeutic efficacy of Levothyroxine can be increased when used in
combination with Fluticasone furoate.</td></tr><tr><td>PG001</td><td>1</td><td>Fluticasone furoate</td><td>Levothyroxine</td><td>The therapeutic efficacy of Levothyroxine can be increased when used in
combination with Fluticasone furoate.</td></tr><tr><td>PG001</td><td>1</td><td>Fluticasone furoate</td><td>Levothyroxine</td><td>The therapeutic efficacy of Levothyroxine can be increased when used in
combination with Fluticasone furoate.</td></tr><tr><td>PG001</td><td>1</td><td>Lercanidipine</td><td>Montelukast</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Montelukast is combined with Lercanidipine.</td></tr><tr><td>PG001</td><td>1</td><td>Lercanidipine</td><td>Silodosin</td><td>The risk or severity of orthostatic hypotension and dizziness can be increased
when Lercanidipine is combined with Silodosin.</td></tr><tr><td>PG001</td><td>1</td><td>Lercanidipine</td><td>Vilanterol</td><td>Vilanterol may decrease the antihypertensive activities of Lercanidipine.</td></tr><tr><td>PG001</td><td>1</td><td>Montelukast</td><td>Enalapril</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Montelukast is combined with Enalapril.</td></tr><tr><td>PG001</td><td>1</td><td>Montelukast</td><td>Levothyroxine</td><td>The metabolism of Montelukast can be decreased when combined with Levothyroxine.</td></tr><tr><td>PG001</td><td>1</td><td>Montelukast</td><td>Levothyroxine</td><td>The metabolism of Montelukast can be decreased when combined with Levothyroxine.</td></tr><tr><td>PG001</td><td>1</td><td>Montelukast</td><td>Levothyroxine</td><td>The metabolism of Montelukast can be decreased when combined with Levothyroxine.</td></tr><tr><td>PG001</td><td>1</td><td>Montelukast</td><td>Levothyroxine</td><td>The metabolism of Montelukast can be decreased when combined with Levothyroxine.</td></tr><tr><td>PG001</td><td>1</td><td>Silodosin</td><td>Enalapril</td><td>The risk or severity of orthostatic hypotension and dizziness can be increased
when Enalapril is combined with Silodosin.</td></tr><tr><td>PG001</td><td>1</td><td>Silodosin</td><td>Vilanterol</td><td>The therapeutic efficacy of Vilanterol can be decreased when used in combination
with Silodosin.</td></tr><tr><td>PG001</td><td>1</td><td>Vilanterol</td><td>Enalapril</td><td>Vilanterol may decrease the antihypertensive activities of Enalapril.</td></tr></tbody></table></div>
